| Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|
Expenses | ||||||
Research and development expenses | ||||||
39,715 | 36,098 | 34,993 | 27,405 | 0 | 0 | 0 |
Investment tax credits | ||||||
1,743 | 1,471 | 1,338 | 1,237 | 0 | 0 | 0 |
Research and development expense, net | ||||||
37,972 | 34,626 | 33,655 | 26,168 | 0 | 0 | 0 |
General and administrative expenses | ||||||
13,612 | 11,981 | 10,475 | 9,287 | 0 | 0 | 0 |
Interest income | ||||||
2,200 | 1,984 | 1,552 | 1,082 | 0 | 0 | 0 |
Financial expenses | ||||||
-68 | -29,480 | -44,130 | -80,437 | 0 | 0 | 0 |
Net loss before income taxes | ||||||
-49,453 | -74,104 | -86,709 | -114,811 | 0 | 0 | 0 |
Income tax expense | ||||||
1,111 | 688 | 640 | 643 | 0 | 0 | 0 |
Net loss and comprehensive loss | ||||||
-50,564 | -74,793 | -87,349 | -115,455 | 0 | 0 | 0 |
Basic and diluted loss per share (in dollars per share) | ||||||
-0.46 | -0.34 | -0.42 | 20.92 | -1.83 | -9.54 | -17.48 |
Weighted average number of outstanding basic and diluted shares (in shares) | ||||||
31,717 | 31,717 | 31,717 | 32,114 | 21,317 | 2,445 | 2,364 |